Active — Not RecruitingNot Applicable

Balance Acceptance and Commitment Therapy for Long COVID

United Kingdom196 participantsStarted 2024-06-04

Plain-language summary

This randomised controlled trial aims to investigate the efficacy of a psychological intervention for long COVID (LC) / post-COVID-19 syndrome (PCS) called Balance Acceptance and Commitment Therapy (Balance ACT). The primary objective of this trial is to investigate whether Balance-ACT improves quality of life over treatment as usual (i.e., self-help leaflet) in people with PCS/LC.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18 or older
✓. LC/PCS diagnosis as defined by National Health Service (NHS) / National Institute for Health and Care Excellence (NICE) (i.e., symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis). A checklist will be used to ensure participants fulfil the diagnostic criteria as per the NICE guidelines
✓. Ability to travel to the research site for the study assessments
✓. Having registered with a General Practitioner (GP) in the United Kingdom (UK) and consent to provide their details for the study team to contact
✓. Ability to provide informed consent
✓. Ability to read and write English

Exclusion criteria

✕. Current diagnosis of an active major mental health disorder likely to interfere with participation
✕. Unstable alcohol / drug dependency
✕. Unstable complications associated with LC/PCS
✕. Past hospitalisation for COVID-19
✕. Current or recent participation in other treatment intervention studies (\<4 weeks after completion)
✕. Currently receiving psychological support or psychotherapy

What they're measuring

Physical Component Summary (PCS) of the 36-item Short Form Health Survey (SF-36) at Week 14

Timeframe: Week 14

Trial details

NCT IDNCT06231238

SponsorKing's College London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-30

View on ClinicalTrials.gov More Post-COVID-19 Syndrome trials